WT1 and neoplasm: Treatment modalities such as microRNA-loaded minicells targeting epidermal growth factor receptor (EGFR) for tumor suppression, Wilms’ tumor 1 vaccines, and tyrosine kinase inhibitors could prove to be valuable additions to the standard therapeutic approaches for MPM34,50.